SecBot SecBot
8-K ·Filed Nov 10, 2026

GOSS

Gossamer Bio, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6d 7h ago SEC0001728117-26-000116
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key binary catalyst is FDA acceptance of the seralutinib NDA, which would unlock up to $125M in committed capital. Monitor for FDA filing decision in the coming weeks; acceptance would significantly extend the cash runway into a potential 2027 launch.

DirectionNeutral
Confidencehigh
Horizonweeks

seralutinib

▼ Bearish Named in this 8-K
Impact
Phase
Phase 3 (completed; missed primary endpoint)
Time to market
Target NDA submission September 2026; potential FDA approval Q3 2027 if accepted — but highly uncertain given the failed Phase 3.
Next catalyst
None dated

What to watchWatch for the public disclosure of the pre-NDA meeting outcome (mid-June 2026 meeting). If the FDA pushes back on filing, the stock could fall further. If the FDA allows the NDA submission to proceed, a September filing announcement could trigger a short-term bounce. Either way, this is a distressed penny stock, position sizing should account for potential total loss.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$11.69
T+0 close · Nov 10, 2026 · via day close
Latest settled
−3.85%
T+1 · $11.24
Vs SPY
−3.50%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $11.69entry
  2. T+1 · 5d ago −3.85%α −3.50% · $11.24
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Gossamer Bio reported Q3 2026 results with a net loss of $48.1M ($7.36 per share), compared to a net loss of $48.2M ($16.92 per share) in Q3 2025. The NDA for seralutinib in PAH was submitted in September 2026, and the company has a structured private placement that could provide up to $125M upon FDA acceptance of the NDA. Cash stood at $51.2M as of September 30, 2026.

Key Financial Metrics

EPS
−$7.36
Revenue
$38.4M
est $12.2M · +215.0% · +189.0% YoY

Key Facts

  • NDA for seralutinib in PAH submitted to FDA in September 2026
  • Net loss of $48.1M for Q3 2026 vs $48.2M in Q3 2025
  • Cash, cash equivalents and marketable securities of $51.2M as of September 30, 2026
  • Structured private placement: $25M upfront, up to $125M additional upon FDA acceptance of NDA
  • 1-for-80 reverse stock split completed in September 2026
  • Revenue from contracts with collaborators was $38.4M, up from $13.3M in Q3 2025, primarily from Chiesi termination
  • R&D expenses decreased to $18.8M from $45.5M in Q3 2025

Financial Impact

Net loss of $48.1M; cash burn of $5.8M from $57.0M to $51.2M during Q3 2026

cashnet lossrevenue

Risk Factors

  • FDA may not accept the NDA for filing, which would prevent the $125M capital tranche
  • Even if accepted, FDA approval is not guaranteed and the Phase 3 PROSERA study's statistical significance was characterized as a review issue
  • Cash runway only into Q1 2027 without additional capital; the company is dependent on the NDA milestone for funding
  • D. E. Shaw has been de-escalating its activist stake, now below 5%

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001728117-26-000116
Document: goss-20261110.htm0001728117-26-000116
Document: 0001728117-26-000116-index-headers.html0001728117-26-000116
Document: 0001728117-26-000116-index.html0001728117-26-000116
Document: 0001728117-26-000116.txt0001728117-26-000116
8-K Data (Synthetic)0001728117-26-000116

Track record

20 reports on GOSS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.28% at T+60 after the Jun 17, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today S-3 Neutral 3/10 Entry $10.98 Now $10.98 −0.00% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $11.69 Now $10.98 −6.07% settles Feb 9
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $10.65 Now $10.98 +3.15% settles Feb 5
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $9.77 Now $10.98 +12.38% settles Feb 4
  5. Oct 29, 202618d ago SC 13D/A Bearish 5/10 Entry $10.38 Now $10.98 −5.78% settles Jan 28
  6. Oct 8, 20265w ago SC 13D/A Bearish 5/10 Entry $9.31 Now $10.98 −17.94% settles Jan 6
  7. Sep 28, 20267w ago SC 13D/A Bearish 6/10 Entry $11.58 Now $10.98 +5.18% settles Dec 23
  8. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $11.69 Now $10.98 −6.07% settles Dec 16
  9. Sep 16, 20268w ago 8-K Neutral 4/10 Entry $11.94 Now $10.98 −8.04% settles Dec 11
  10. Sep 11, 20269w ago 8-K Bearish 6/10 Entry $10.73 Now $10.98 −2.33% settles Dec 7
Showing 10 of 20

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026